简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
abstrak:Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now
Wockhardt (NS:) shares jumped by 14% today as it completed the phase-3 pneumonia study of macrolide antibiotic Nafithromycin. However, if we talk about the valuations, as per InvestingPro+ some other companies in the Pharma sector may have more upside potential now. According to the Compare feature of InvestingPro+, Zydus Lifesciences Ltd (NS:) and Biocon (NS:) are attractively placed with potential upside of 24% and 21% respectively. Wockhardt, according to InvestingPro+ may have crossed its intrinsic value to be in the overvalued region now.
Disclaimer:
Ang mga pananaw sa artikulong ito ay kumakatawan lamang sa mga personal na pananaw ng may-akda at hindi bumubuo ng payo sa pamumuhunan para sa platform na ito. Ang platform na ito ay hindi ginagarantiyahan ang kawastuhan, pagkakumpleto at pagiging maagap na impormasyon ng artikulo, o mananagot din para sa anumang pagkawala na sanhi ng paggamit o pag-asa ng impormasyon ng artikulo.
EC Markets
FOREX.com
Exness
IC Markets Global
FP Markets
Doo Prime
EC Markets
FOREX.com
Exness
IC Markets Global
FP Markets
Doo Prime
EC Markets
FOREX.com
Exness
IC Markets Global
FP Markets
Doo Prime
EC Markets
FOREX.com
Exness
IC Markets Global
FP Markets
Doo Prime